Programma Scientifico | Impact 2025
Il programma scirntifico dell'evento
Programma Scientifico
13.45-14.00
Saluti e Obiettivi del Convegno - M. Andreoni, A. Antinori, C.F. Perno
14.00-15.10
SESSION I - The long-acting ARV drugs landscape for pre-exposure prophylaxis
Moderator: A. Gori
Moderator: A. Gori
14.00-14.15
State-of-art of PrEP in Italy: the PrIDE challenge S. Nozza
14.15-14.20
Discussion
14.20-14.35
The present and the future of long-acting PrEP V. Mazzotta
14.35-14.40
Discussion
14.40-14.55
Risk of failure and resistance during PrEP: facts or hypotheses D. Moschese
14.55-15.10
General Discussion
15.10-16.45
SESSION II - ARV new drugs: innovating regimens across the lines
Moderator: C.M. Mastroianni
Moderator: C.M. Mastroianni
15.10-15.25
Do we need new drugs? The outlook of the current drugs and the unmet needs G. Di Perri
15.25-15.30
Discussion
15.30-15.45
What upcoming drugs are coming now? S. Lo Caputo
15.45-15.50
Discussion
15.50-16.05
What upcoming drugs will we have in the future? A. Castagna
16.05-16.10
Discussion
16.10-16.25
New diagnostic approaches for ART with new drugs L. Fabeni
16.25-16.45
General Discussion
16.45-17.10
Coffee break
17.10-18.20
SESSION III - Management of low-level HIV viremia during ART: Delphi consensus statement and appraisal of the evidence
Moderator: G. Antonelli
Moderator: G. Antonelli
17.10-17.25
Low-level HIV-1 viraemia remains a challenge, with its clinical interpretation being uncertain L. Sarmati
17.25-17.30
Discussion
17.30-17.45
How to manage viral load and resistance testing during low-level viremia F. Ceccherini Silberstein
17.45-17.50
Discussion
17.50-18.05
Need for tailored interventions to improve adherence to ART in case of low-level viremia A. Cingolani
18.05-18.20
General Discussion
18.20-19.05
SESSION IV - HIV treatment optimization
Moderator: A. Cattelan
Moderator: A. Cattelan
18.20-18.35
The importance of long-term suppression of HIV replication C. Mussini
18.35-18.40
Discussion
18.40-18.55
Diagnostic strategy to support the achievement of long-term success A.M. Geretti
18.55-19.05
General Discussion
19.05-19.20
Closing Remarks M. Andreoni, A. Antinori, C.F. Perno
09.00-10.10
SESSION V - Update on HIV-drug resistance
Moderator: E. Girardi
Moderator: E. Girardi
09.00-09.15
New drugs, new resistance S. Rusconi
09.15-09.20
Discussion
09.20-09.35
Resistance mutations of long-acting ART: should we worry? A. Di Biagio
09.35-09.40
Discussion
09.40-09.55
Should we study the HIV-drug resistance in the reservoir? M. Santoro
09.55-10.10
General Discussion
10.10-11.20
SESSION VI - Emerging insights in HBV and HDV infections
Moderator: R. Parrella
Moderator: R. Parrella
10.10-10.25
HDV: How can the patient under treatment be monitored? N. Coppola
10.25-10.30
Discussion
10.30-10.45
HBV: Diagnostic approach for a complex disease V. Svicher
10.45-10.50
Discussion
10.50-11.05
The relevance of HBV occult infection in today’s anti-HIV therapy V. Malagnino
11.05-11.20
General Discussion
11.20-11.45
Coffee break
11.45-12.15
SESSION VII
Moderator: A. Caruso
Moderator: A. Caruso
11.45-12.05
Lecture: Metagenomics for the diagnosis of infectious diseases: the (small) present and the (wide) future M. Zazzi
12.05-12.15
Discussion
12.15-13.25
SESSION VIII - Update about COVID-19
Moderator: F. Maggi
Moderator: F. Maggi
12.15-12.30
Temporal dynamics of SARS-CoV-2 variants M. Rueca
12.30-12.35
Discussion
12.35-12.50
Treatment of COVID-19: where are we at? C. Torti
12.50-12.55
Discussion
12.55-13.10
New vaccination strategies for the containment of SARS-CoV-2 infection C. Alteri
13.10-13.25
General Discussion
13.25-14.30
Lunch
14.30-16.05
SESSION IX - Vaccinations: efficacy/effectiveness and pitfalls
Moderator: A. Cascio
Moderator: A. Cascio
14.30-14.45
Shingles vaccination: for which patients? M. Iannetta
14.45-14.50
Discussion
14.50-15.05
RSV vaccination: What’s new? I. Gentile
15.05-15.10
Discussion
15.10-15.25
Appropriateness in pneumococcal vaccination in immunosuppressed patients G.C. Marchetti
15.25-15.30
Discussion
15.30-15.45
MVA vaccination for mpox: long-term immunogenicity and need for booster G. Matusali
15.45-16.05
General Discussion
16.05-16.20
Closing Remarks M. Andreoni, A. Antinori, C.F. Perno
